These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 12912808)

  • 1. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control.
    Cipollone F; Iezzi A; Fazia M; Zucchelli M; Pini B; Cuccurullo C; De Cesare D; De Blasis G; Muraro R; Bei R; Chiarelli F; Schmidt AM; Cuccurullo F; Mezzetti A
    Circulation; 2003 Sep; 108(9):1070-7. PubMed ID: 12912808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans.
    Cipollone F; Fazia M; Iezzi A; Zucchelli M; Pini B; De Cesare D; Ucchino S; Spigonardo F; Bajocchi G; Bei R; Muraro R; Artese L; Piattelli A; Chiarelli F; Cuccurullo F; Mezzetti A
    Circulation; 2003 Mar; 107(11):1479-85. PubMed ID: 12654603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity.
    Cipollone F; Fazia M; Iezzi A; Pini B; Cuccurullo C; Zucchelli M; de Cesare D; Ucchino S; Spigonardo F; De Luca M; Muraro R; Bei R; Bucci M; Cuccurullo F; Mezzetti A
    Circulation; 2004 Mar; 109(12):1482-8. PubMed ID: 15037537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability.
    Cipollone F; Prontera C; Pini B; Marini M; Fazia M; De Cesare D; Iezzi A; Ucchino S; Boccoli G; Saba V; Chiarelli F; Cuccurullo F; Mezzetti A
    Circulation; 2001 Aug; 104(8):921-7. PubMed ID: 11514380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes.
    Cuccurullo C; Iezzi A; Fazia ML; De Cesare D; Di Francesco A; Muraro R; Bei R; Ucchino S; Spigonardo F; Chiarelli F; Schmidt AM; Cuccurullo F; Mezzetti A; Cipollone F
    Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2716-23. PubMed ID: 17038636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Balance between PGD synthase and PGE synthase is a major determinant of atherosclerotic plaque instability in humans.
    Cipollone F; Fazia M; Iezzi A; Ciabattoni G; Pini B; Cuccurullo C; Ucchino S; Spigonardo F; De Luca M; Prontera C; Chiarelli F; Cuccurullo F; Mezzetti A
    Arterioscler Thromb Vasc Biol; 2004 Jul; 24(7):1259-65. PubMed ID: 15155382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human.
    Cipollone F; Fazia ML; Iezzi A; Cuccurullo C; De Cesare D; Ucchino S; Spigonardo F; Marchetti A; Buttitta F; Paloscia L; Mascellanti M; Cuccurullo F; Mezzetti A
    Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1925-31. PubMed ID: 16020747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of COX-2, Prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: regulation by nuclear factor-kappaB.
    Gómez-Hernández A; Martín-Ventura JL; Sánchez-Galán E; Vidal C; Ortego M; Blanco-Colio LM; Ortega L; Tuñón J; Egido J
    Atherosclerosis; 2006 Jul; 187(1):139-49. PubMed ID: 16212965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New insights on the molecular mechanisms of type-1 angiotensin II receptor blockers and their contribution to atherosclerotic plaque stabilization].
    Mezzetti A; Fazia M; Cipollone F
    Recenti Prog Med; 2004 Dec; 95(12):586-90. PubMed ID: 15666492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coexpression of cyclooxygenase-2 and matrix metalloproteinases in human aortic atherosclerotic lesions.
    Hong BK; Kwon HM; Lee BK; Kim D; Kim IJ; Kang SM; Jang Y; Cho SH; Kim HK; Jang BC; Cho SY; Kim HS; Kim MS; Kwon HC; Lee N
    Yonsei Med J; 2000 Feb; 41(1):82-8. PubMed ID: 10731924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of advanced glycation end products on the expression of COX-2, PGE2 and NO in human osteoarthritic chondrocytes.
    Nah SS; Choi IY; Lee CK; Oh JS; Kim YG; Moon HB; Yoo B
    Rheumatology (Oxford); 2008 Apr; 47(4):425-31. PubMed ID: 18285354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coexpression of microsomal prostaglandin E synthase with cyclooxygenase-2 in human rheumatoid synovial cells.
    Kojima F; Naraba H; Sasaki Y; Okamoto R; Koshino T; Kawai S
    J Rheumatol; 2002 Sep; 29(9):1836-42. PubMed ID: 12233875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coordinated up-regulation of cyclooxygenase-2 and microsomal prostaglandin E synthase 1 transcription by nuclear factor kappa B and early growth response-1 in macrophages.
    Díaz-Muñoz MD; Osma-García IC; Cacheiro-Llaguno C; Fresno M; Iñiguez MA
    Cell Signal; 2010 Oct; 22(10):1427-36. PubMed ID: 20546888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microsomal prostaglandin E synthase-1, which is not coupled to a particular cyclooxygenase isoenzyme, is essential for prostaglandin E(2) biosynthesis in vascular smooth muscle cells.
    Camacho M; Gerbolés E; Escudero JR; Antón R; García-Moll X; Vila L
    J Thromb Haemost; 2007 Jul; 5(7):1411-9. PubMed ID: 17403097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [COX-2 and mPGES-1 expression in carotid atherosclerotic plaques].
    Liu HF; Li XH; Yang QD; Miao W; Qi SS; Song XM; He GS; Dong HL; Zhang FQ
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Aug; 24(4):453-6. PubMed ID: 17680542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Membrane prostaglandin E synthase-1: a novel therapeutic target.
    Samuelsson B; Morgenstern R; Jakobsson PJ
    Pharmacol Rev; 2007 Sep; 59(3):207-24. PubMed ID: 17878511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expanding expression of the 5-lipoxygenase/leukotriene B4 pathway in atherosclerotic lesions of diabetic patients promotes plaque instability.
    Zhou YJ; Wang JH; Li L; Yang HW; Wen de L; He QC
    Biochem Biophys Res Commun; 2007 Nov; 363(1):30-6. PubMed ID: 17825794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostaglandin E2 is an enhancer of interleukin-1beta-induced expression of membrane-associated prostaglandin E synthase in rheumatoid synovial fibroblasts.
    Kojima F; Naraba H; Sasaki Y; Beppu M; Aoki H; Kawai S
    Arthritis Rheum; 2003 Oct; 48(10):2819-28. PubMed ID: 14558087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2.
    Murakami M; Naraba H; Tanioka T; Semmyo N; Nakatani Y; Kojima F; Ikeda T; Fueki M; Ueno A; Oh S; Kudo I
    J Biol Chem; 2000 Oct; 275(42):32783-92. PubMed ID: 10869354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment.
    Marfella R; D'Amico M; Esposito K; Baldi A; Di Filippo C; Siniscalchi M; Sasso FC; Portoghese M; Cirillo F; Cacciapuoti F; Carbonara O; Crescenzi B; Baldi F; Ceriello A; Nicoletti GF; D'Andrea F; Verza M; Coppola L; Rossi F; Giugliano D
    Diabetes; 2006 Mar; 55(3):622-32. PubMed ID: 16505224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.